MedPath

The INITIATE Study: Initiating Nicotine Dependence Treatment for Smokers Admitted to Emergency Departments

Not Applicable
Recruiting
Conditions
Nicotine Withdrawal
Nicotine Dependence, Cigarettes
Registration Number
NCT04163081
Lead Sponsor
Ottawa Heart Institute Research Corporation
Brief Summary

The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED) and other high-volume hospital and community ambulatory care settings. The intervention includes a behavioural incentive and tailored follow-up support on long-term smoking abstinence, health, healthcare utilization, and cost. Tobacco-related illnesses cost the healthcare system millions each year. Quitting smoking improves smoking-related outcomes, like the onset or management of heart disease, stroke, lung diseases, and several cancers. There are approximately 16 million visits to Canadian EDs each year; an estimated 3-4 million of these involve smokers. Effective quit smoking interventions exist, but are underutilized. Few hospital EDs, community healthcare centers, and other inpatient and outpatient clinics in Canada offer tobacco-use interventions. In order for clinicians to offer quit smoking support, interventions need to be simple given the realities of these high-volume environments. Considering that stopping smoking improves health outcomes, that tobacco-use is an important cause of preventable ED use, and the volume of smokers, Canadian EDs and other high-volume hospital and community ambulatory care settings are a missed opportunity in the initiation of quit smoking support. Our intervention has been designed to optimize uptake and smoking abstinence by including the most effective evidence-based behavioural and drug-related approaches, removing specific barriers and challenges that smokers face when trying to quit (e.g., affordability, low confidence and motivation), while packaging the intervention in a quick-to-initiate manner, making it ideal for fast-paced, complex environments.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1208
Inclusion Criteria
  • Current daily smoker (smokes ≥ 5 cigarettes per day);
  • ≥ 18 years of age (the age of majority in Ontario);
  • For ED sites only, assigned a CTAS level of 2-5 (emergent to non-urgent);
  • Able to read and understand English or French;
  • Resides in Ontario and eligible for Ontario Health Insurance Plan (to permit linkage with administrative data housed at the Institute for Clinical Evaluative Sciences [ICES]);
  • Available and willing to participate in follow-up assessments over the next 12 months;
  • Has access to a telephone or computer;
  • Able to provide informed consent
Exclusion Criteria
  • Currently participating in this or another smoking cessation study;
  • For ED sites only, assigned a CTAS level of 1 (resuscitation - the most seriously ill patients with highest likelihood of hospital admission) or in psychiatric emergency unit;
  • Pregnant, planning to become pregnant over the next year, or breastfeeding;
  • Has morbid illness which will prevent completion of 26-week follow-up (e.g., receiving palliative care);
  • In the opinion of the attending physician, manifests acute physical and/or psychiatric illness or has cognitive impairment that would preclude participation in/benefit from the intervention.
  • Scheduled for a known elected surgery, procedure, or future hospitalization during the study period.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Smoking Abstinence26 weeks (6 months) after study enrollment

Smoking abstinence at 26 weeks, biochemically verified using an expired air carbon monoxide (CO) test

Secondary Outcome Measures
NameTimeMethod
Prolonged Abstinence4, 26, and 52 weeks after study enrollment

Prolonged (since last time point) smoking abstinence, at 4, 26, and 52 weeks

Health Services Outcomes - ED visits4, 26, and 52 weeks after study enrollment

Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) visits to ED at 4, 26, and 52 weeks

Point Prevalence Abstinence4, and 52 weeks after study enrollment

Point prevalence smoking abstinence, at 4, and 52 weeks

Number of Quit Attempts4, 26, and 52 weeks after study enrollment

Number of quit attempts since study entry, at 4, 26, and 52 weeks

Cessation Medication and/or E-cigarette Use4, 26, and 52 weeks after study enrollment

Use of smoking cessation medication and/or e-cigarette, at 4, 26, and 52 weeks

Health-Related Quality of Life52 weeks after study enrollment

Health-related quality of life (HR-QoL), at 52 weeks. This will be measured using the Hospital Anxiety and Depression Scale (HADS), designed to identify and measure the levels of anxiety and depression among individuals in non-psychiatric hospital settings, and the Health Questionnaire Assessment (EQ-5D-5L), using five graded severity levels to summarize perceived health across five foundational dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

Smoking Reduction4, 26, and 52 weeks after study enrollment

Smoking reduction (i.e., change in number of daily cigarettes), at 4, 26, and 52 weeks

Use of Behavioural Supports4, 26, and 52 weeks after study enrollment

Use of behavioural supports (e.g., counseling, quit lines), at 4, 26, and 52 weeks

Health Services Outcomes - Hospital Admissions4, 26, and 52 weeks after study enrollment

Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) admissions to hospital at 4, 26, and 52 weeks

Health Services Outcomes - Deaths4, 26, and 52 weeks after study enrollment

Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) deaths at 4, 26, and 52 weeks

Cost-Effectiveness Ratios52 weeks after study enrollment

Cost-effectiveness ratios related to health services at 52 weeks

Trial Locations

Locations (4)

Riverside Hospital

🇨🇦

Ottawa, Ontario, Canada

University of Ottawa Heart Institute

🇨🇦

Ottawa, Ont', Canada

Civic Hospital

🇨🇦

Ottawa, Ontario, Canada

General Hospital

🇨🇦

Ottawa, Ontario, Canada

Riverside Hospital
🇨🇦Ottawa, Ontario, Canada
Dr. Venkatesh Thiruganasambandamoorthy
Contact
6137985555,17023
vthirug@toh.ca

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.